Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C
The invention is directed in part to methods for treating and/or controlling hepatitis C in a patient. The methods are directed in part to combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and at least one other active agent.
1 . A method of treating a hepatitis C infection, comprising administering to a patient in need thereof: i) a MTP inhibitor and ii) at least one other active agent.
2 . The method of claim 1 , wherein the at least one other active agent is a hepatitis C treatment agent and/or a cholesterol lowering agent.
3 . The method of claim 1 , wherein the at least one other active agent is selected from at least one of: a cholesterol absorption inhibitor, a HMG-CoA reductase inhibitor, a bile acid sequestrant, a fibric acid derivative, niacin, a squalene synthase inhibitor, an ACAT inhibitor, a CETP inhibitor, an inosine monophosphate dehydrogenase inhibitor, a NS3 or 4A protease inhibitor, alpha-interferon, pegylated alpha-inteferon, a NS5B RNA polymerase inhibitor A-689, A-831, siRNA, a miR-122 inhibitor, a toll-like receptor inhibitor, celgosivir, thymalfasin, bavituximab, NIM811, nitazoxanide, GSK625433, alpha-glucosidase inhibitors, ribosome entry site inhibitors, immunomodulators, AVI-4065, NM-283, amantadine, pioglitazone and a hepatitis C vaccine.
4 . The method of claim 1 , wherein the patient is a human.
5 . The method of claim 1 , wherein the hepatitis C infection is a chronic hepatitis C infection.
6 . The method of claim 1 , wherein the MTP inhibitor and the other active agent is administered sequentially.
7 . The method of claim 1 , wherein the MTP inhibitor and the other active agent is administered substantially simultaneously.
8 - 10 . (canceled)
11 . The method of claim 1 , wherein administering the MTP inhibitor in combination with the other active agent provides a synergistic therapeutic effect.
12 . The method of claim 11 , wherein the MTP inhibitor is administered in a synergistically effective amount.
13 . The method of claim 11 , wherein the other active agent is administered in a synergistically effective amount.
14 . The method of claim 1 , wherein at least two other active agents are administered.
15 . The method of claim 1 , wherein at least two of the active agents are administered substantially simultaneously.
16 . The method claim 1 , wherein the MTP inhibitor is administered substantially simultaneously with at least two other active agents.
17 - 49 . (canceled)
50 . A method of treating a hepatitis C infection comprising administering to a patient in need thereof a MTP inhibitor in combination with at least one additional active agent, wherein the administration of the combination results in a greater reduction in the hepatitis C viral load of the patient as compared to administration of the additional active agent or the MTP inhibitor alone.
51 . The method of claim 50 , wherein the reduction in the hepatitis C viral load is greater than that achieved by administering the active agent alone or the MTP inhibitor alone.
52 . The method of claim 50 , wherein the reduction in the hepatitis C viral load is greater than the additive effect of administering the MTP inhibitor alone and the active agent alone.
53 . The method of claim 50 , wherein the viral load is measured using molecular nucleic acid testing methods.
54 . The method of claim 50 , wherein the viral load is measured at about 14 days, 28 days, 4 months and/or 6 months from a first administration.
55 . The method of claim 50 , wherein the additional active agent comprises a) interferon or pegylated interferon and b) ribavirin.
56 . A method of treating hepatitis C comprising administering to a patient in need thereof a MTP inhibitor in combination with at least one additional active agent, wherein the administration of the combination results a shorter treatment duration as compared to administration of the additional active agent or the MTP inhibitor alone.
57 - 64 . (canceled)